PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Pohla, H.* ; Frankenberger, B. ; Stadlbauer, B.* ; Oberneder, R.* ; Hofstetter, A.* ; Willimsky, G.* ; Pezzutto, A.* ; Dörken, B.* ; Blankenstein, T.* ; Schendel, D.J.

Allogeneic vaccianation for renal cell carcinoma: development and monitoring.

Bone Marrow Transplant. 25, 2, 83-87 (2000)
Verlagsversion DOI
Closed
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
An allogeneic tumor cell vaccine should display a natu- ral immunogenicity that allows the stimulation of tumor-reactive effector cells in patients. Furthermore, the vaccine should express antigens that are shared by many tumors to which patients are not tolerant. A var- iety of tumor peptides should be presented by different HLA-molecules due to limited MHC matching with recipients and last but not least, the vaccine should have a strong growth potential in vitro to allow adequate amounts of vaccine to be generated for long-term usage. In vitro and in situ studies with the renal cell carcinoma cell line RCC-26 demonstrate: (1) RCC-26 can induce complex allospecific responses through direct priming; (2) RCC-26 can not only reactivate cytotoxic T lympho- cytes (CTL) of a memory phenotype but they also can induce de novo tumor-antigen associated responses in normal donors; (3) these cells present epitopes restric- ted by several MHC molecules, allowing the vaccination of patients matched for different HLA alleles; and (4) they stimulate HLA-A*0201-restricted T cells bear- ing characteristic T cell receptors (TCR). Thus, in addition to using limiting dilution killer and ELISPOT assays, molecular tracking of a tumor-specific TCR can be used to judge the development of antitumor reac- tivity and vaccine efficiency.
Impact Factor
Scopus SNIP
Altmetric
2.277
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter renal cell carcinoma allogeneic vaccination immune monitoring chromium release lanthanide release ELISPOT TCR tracking
Sprache englisch
Veröffentlichungsjahr 2000
HGF-Berichtsjahr 0
ISSN (print) / ISBN 0268-3369
e-ISSN 1476-5365
Zeitschrift Bone Marrow Transplantation
Quellenangaben Band: 25, Heft: , Seiten: 83-87, Artikelnummer: , Supplement: 2
Verlag Nature Publishing Group
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Molecular Immunology (IMI)
POF Topic(s)
30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Forschungsfeld(er)
Immune Response and Infection
PSP-Element(e) G-501700-006
FE 71721
Erfassungsdatum 2000-12-31
[➜Korrektur melden]